Innate Pharma SA

Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
  • TickerIPH
  • ISINFR0010331421
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Innate Pharma: 1 director bought

A director at Innate Pharma bought 50,000 shares at 5.600EUR and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

Ahmed Ben Salem ...
  • Azza Khalfallah
  • Fehmi Ben Naamane
  • Jean-François Granjon
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Oussema Denguir
  • Stephane Houri
  • Yassine Batini

ODDO BHF Small & MIDCAP MORNING NEWS - 10/21/2019

...

Ahmed Ben Salem ...
  • Azza Khalfallah
  • Fehmi Ben Naamane
  • Jean-François Granjon
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Oussema Denguir
  • Stephane Houri
  • Yassine Batini

ODDO BHF Small & MIDCAP MORNING NEWS - 21/10/2019

...

Martial Descoutures ...
  • Oussema Denguir

Innate Pharma : A US IPO in challenging conditions

>A deal which undershot our expectations - Innate Pharma closed its US IPO at the end of last week. While we initially hoped to see nearly €70m in funds raised without factoring in the over-allotment with a price in the range of € 5.87-€6.9 per share, we are somewhat disappointed with the terms granted, which could penalise the price for some time. Through this transaction, Innate raised a total of $ 79.1m (€ 71.4m gross) through the issue of 14,375 million new ...

Martial Descoutures ...
  • Oussema Denguir

Innate Pharma : Une IPO US dans des conditions difficiles

>Une opération qui ressort en dessous de nos attentes - Innate Pharma a donc clôturé son IPO US en fin de semaine dernière. Alors que nous espérions initialement une levée proche de 70 M€ sans considérer la surallocation avec un prix compris dans une fourchette de de 5.87 € et 6.9 € par action, nous ressortons un peu déçus des modalités octroyées qui pourraient pénaliser le cours quelques temps. A travers cette opération, Innate a donc levé un total de 79.1 M$ (...

Eric Le Berrigaud

INNATE PHARMA: FV adjustment to the dilutive global offering | BUY | EUR15.6 vs. EUR17.9 (+177%)

INNATE PHARMA - BUY | EUR15.6 vs. EUR17.9 (+177%) FV adjustment to the dilutive global offering Capital increase and Nasdaq listing under tough conditions Trading to resume in Europe this morning Adjustment to our FV Unchanged story, lots of opportunities

Innate Pharma: 1 director bought

A director at Innate Pharma bought 50,000 shares at 5.600EUR and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

Increased risk weighs on INNATE PHARMA, penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of INNATE PHARMA (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date October 22, 2019, the closing price was EUR 5.57 and its target price was estimated at EUR 5.04.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Ipsen S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Ipsen S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Ipsen S.A. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights ...

Eric Le Berrigaud ...
  • Gary Waanders
  • Hugo Solvet
  • Jean-Jacques Le Fur
  • Ross Blair
  • Victor Floc’h

Healthcare: Top Picks Q2 2019: Alcon, Innate, Ipsen and Roche

Healthcare Top Picks Q2 2019: Alcon, Innate, Ipsen and Roche Looking back to Q1 2019 What to expect for Q2 2019

MarketLine Department

Onxeo SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Onxeo SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Onxeo SA since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights This ...

Eric Le Berrigaud

Pharmaceuticals | ESMO 2018: Sequencing Was the Key Word

We synthesise here the main take-away messages from the annual ESMO congress which took place in Munich in October. We present the conclusions in sections organised by organ with three main parts: renal-cell carcinoma (RCC), breast cancer (BC) and lung cancer (NSCLC) with non-uniform levels of innovation and progress. The last section is dedicated to head & neck cancer with encouraging updated data on monatuximab/cetuxima

Jehanne Leroy

Innate Pharma - Assemblée Générale des actionnaires du 22 mai 2019

RémunérationsDans le cadre de la politique de rémunération 2019 des dirigeants, la société propose l’ajout d’une condition de performance additionnelle pour les attributions d’actions de performance. Ce nouveau critère réduit la probabilité d’acquisition des actions de performance et compense donc la hausse de l’enveloppe d’actions de performance proposée pour le Président du Directoire. Ainsi, si dans l’absolu, cette politique permet l’attribution de montants excessifs, et présente une structure ne respectant pas nos principes, les changements proposés sont plutôt positifs. Cette politique de...

Jehanne Leroy

Proxy Report - 29/05/2018

Le principal sujet de la présente assemblée est la résolution 33 qui propose la création d'un droit de vote double alors même que la société avait proposé en 2015 une résolution afin de maintenir le principe "Une Action - Une Voix".  Proxinvest considère que le droit de vote double est une rupture grave du principe d'égalité des actionnaires. Cette rupture de l’égalité entre les actionnaires est double puisque, dans un premier temps, les actionnaires au nominatif et ceux au porteur ne sont plus soumis aux mêmes traitements, les actionnaires au porteur n’ayant aucune possibilité d’accéder au d...

Jehanne Leroy

Etude de l'AG du 23/06/2017

Les deux principaux sujets de la présente assemblée sont d'une part le renouvellement de tous les membres du conseil (résolutions 6 à 13) ainsi que les rémunérations (résolutions 16 à 24 et 26 à 31). Le recours à une structure duale assure la séparation des fonctions entre direction et supervision, le conseil est en majorité indépendant (62,5%) et aucun membre ne semble être en situation de cumul de mandat. Ainsi, tous les renouvellements et nominations proposés sont soutenus. Concernant les rémunérations, la principale faiblesse identifiée demeure le Golden Hello tel que pratiqué par la soc...

Matthieu DRIOL

Short term view - INNATE PHARMA SA : Prices are making further progress.

The trend is bullish. Prices are making further progress. The targets are at €9.000 and then €9.720. The break of €4.554 would endanger the trend.

Matthieu DRIOL

Analyse court terme - INNATE PHARMA SA : La progression des cours se poursuit.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 9,000 € puis 9,720 €. La rupture de 4,554 € mettrait la tendance en danger.

Matthieu DRIOL

Short term view - INNATE PHARMA SA : The trend is bullish.

The trend is bullish. Prices are making further progress. The targets are at €9.000 and then €9.720. The break of €4.554 would endanger the trend.

Matthieu DRIOL

Analyse court terme - INNATE PHARMA SA : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 9,000 € puis 9,720 €. La rupture de 4,554 € mettrait la tendance en danger.

Valérie GASTALDY

Analyse moyen terme - INNATE PHARMA SA : Le rebond gagne en vigueur.

La tendance est baissière. Le rebond gagne en vigueur. Il est probable que cette reprise s'achève sur la résistance à 6,900 € et que les prix baissent à nouveau vers 4,171 €. La tendance de fond serait remise en cause en cas de franchissement de 6,900 €.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch